ArticleIJU case reports2026
Recurrent TFE3-Rearranged Renal Cell Carcinoma Responding to Pembrolizumab Plus Lenvatinib After Postoperative Pembrolizumab: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: TFE3-rearranged renal cell carcinoma (RCC) is rare, and evidence guiding systemic therapy is limited. Case Presentation: A 25-year-old man with gross hematuria had a left renal tumor with hilar lymph node metastasis. Robot-assisted radical nephrectomy and hilar lymph node dissection were performed. Histology, immunohistochemistry, and fluorescence in situ hybridization confirmed TFE3-rearranged RCC, pT3aN1. Postoperative pembrolizumab was started because of the high risk of recurrence. Eight months after surgery, lung and retroperitoneal metastases developed. Lenvatinib was added to ongoing pembrolizumab. The metastatic lesions decreased within one month, and a partial response according to Response Evaluation Criteria in Solid Tumors has been maintained for ten months. Conclusion: This case suggests that adding a vascular endothelial growth factor receptor tyrosine kinase inhibitor to pembrolizumab may be a therapeutic option for recurrent TFE3-rearranged RCC, although longer follow-up and molecular characterization are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.